Clovis Oncology, Inc.
(NASDAQ : CLVS)

( )
CLVS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. 0.59%63.001.0%$429.15m
AMGNAmgen, Inc. -1.61%237.601.3%$415.39m
BIIBBiogen, Inc. 0.59%287.191.4%$362.99m
ILMNIllumina, Inc. 1.11%328.333.5%$323.56m
VRTXVertex Pharmaceuticals, Inc. -0.78%233.991.9%$273.36m
REGNRegeneron Pharmaceuticals, Inc. -5.76%363.712.6%$217.27m
EXASEXACT Sciences Corp. -2.45%85.9024.0%$197.11m
ITCIIntra-Cellular Therapies, Inc. -3.12%25.439.0%$173.46m
ALXNAlexion Pharmaceuticals, Inc. -0.23%113.012.0%$173.06m
INCYIncyte Corp. -2.30%78.652.5%$135.12m
SRPTSarepta Therapeutics, Inc. -3.84%122.9914.6%$133.04m
AAgilent Technologies, Inc. -0.56%89.621.6%$120.06m
BMRNBioMarin Pharmaceutical, Inc. -0.82%87.554.3%$106.16m
BLUEbluebird bio, Inc. -2.26%95.8214.2%$95.27m
SGENSeattle Genetics, Inc. -0.30%108.676.1%$90.33m

Company Profile

Clovis Oncology, Inc. is a commercial stage biotechnology company, which engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets. Its product development programs target specific subsets of cancer, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.